Skip to main content

Johanna Friedl-Naderer

Equibles does not estimate personal net worth.

Get an email with a short summary when Dyne Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.

Get DYN alerts

About Johanna Friedl-Naderer

Dyne Therapeutics, Inc. reported in an 8-K filed September 3, 2024 that Johanna Friedl-Naderer was appointed chief commercial officer. The proxy statement of Dyne Therapeutics, Inc. reports total compensation of $1,086,420 for Johanna Friedl-Naderer in fiscal 2025, including a base salary of $610,691. Disclosed compensation is on record for 2 fiscal years. Dyne Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Dyne Therapeutics, Inc. includes John G. Cox (CEO and Board Member), Josh Brumm (CEO), Erick Lucera (CFO and Chief Accounting Officer) and 4 others.

“On September 3, 2024, the Company issued a press release announcing the hiring of Doug Kerr as chief medical officer, Johanna Friedl-Naderer as chief commercial officer and Lucia Celona as chief human resources officer and the resignations of Dr. McNeill, Ms. High and Wildon Farwell, the chief medical officer.”
Dyne Therapeutics, Inc. Form 8-K, filed September 3, 2024 · Read the filing

Affiliation history

Company network

Leadership on record at Dyne Therapeutics, Inc.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2025 Dyne Therapeutics, Inc. (DYN) $610,691 $1,086,420
2024 Dyne Therapeutics, Inc. (DYN) $171,164 $8,190,480

Recent activity